investors & media

More events are coming soon.

corporate profile

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

stock quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

press releases


SOMERVILLE, Mass. --(BUSINESS WIRE)--Sep. 5, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences: Morgan Stanley 21 st Annual Global Healthcare Conference, Monday, September 11

Read more

SOMERVILLE, Mass. --(BUSINESS WIRE)--Aug. 16, 2023-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has communicated that an advisory committee meeting will not be scheduled for lovotibeglogene autotemcel (lovo-cel).

Read more

- Continued strong commercial launch for ZYNTEGLO ® and SKYSONA ® ; 16 patient starts across both programs to date – - Biologics License Application (BLA) for lovo-cel for sickle cell disease accepted for FDA priority review; PDUFA goal date December 20, 2023 - - Ended quarter with $291M in cash,

Read more